- Nimbolide
-
- $65.00
-
2026-07-27
- CAS:25990-37-8
- Purity: 98.88%
- Supply Ability: 10g
|
| | nimbolide Basic information |
| Product Name: | nimbolide | | Synonyms: | nimbolide;(17R)-7α,15β:21,23-Diepoxy-6α-hydroxy-4,8-dimethyl-1-oxo-11-methoxycarbonyl-18,24-dinor-11,12-seco-5α-chola-2,13,20,22-tetrene-4α-carboxylic acid γ-lactone;NSC 309909;2H,5H-Cyclopenta[d']naphtho[1,8-bc:2,3-b']difuran-6-acetic acid, 8-(3-furanyl)-2a,5a,6,6a,8,9,9a,10a,10b,10c-decahydro-2a,5a,6a,7-tetramethyl-2,5-dioxo-, methyl ester, (2aR,5aR,6S,6aR,8R,9aR,10aS,10bR,10cR)-;methyl [(2aR,5aR,6S,6aR,8R,9aR,10aS,10bR,10cR)-8-furan-3-yl-2a,5a,6a,7-tetramethyl-2,5-dioxo-2a,5a,6,6a,8,9,9a,10a,10b,10c-decahydro-2H,5H-cyclopenta[d]naphtho[2,3-b:1,8-b''c'']difuran-6-yl]acetate;Nimbolide (25 mg);Nimbolide, CyclinA and ERK1/2 inhibitor;Nimbolide, 10 mM in DMSO | | CAS: | 25990-37-8 | | MF: | C27H30O7 | | MW: | 466.52 | | EINECS: | | | Product Categories: | Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals | | Mol File: | 25990-37-8.mol |  |
| | nimbolide Chemical Properties |
| Melting point | >223°C (dec.) | | Boiling point | 608.6±55.0 °C(Predicted) | | density | 1.32±0.1 g/cm3(Predicted) | | storage temp. | Hygroscopic, -20°C Freezer, Under Inert Atmosphere | | solubility | Chloroform, Ethyl Acetate | | form | powder | | color | Light Beige to Yellow | | Major Application | metabolomics
vitamins, nutraceuticals, and natural products | | InChIKey | KMTFKEPRKBPCJW-UHFFFAOYSA-N | | SMILES | C12C3(C)C=CC(=O)C1(C)C(CC(=O)OC)C1(C)C4C(C(C=C4C)C4=COC=C4)OC1C2OC3=O |
| WGK Germany | WGK 3 | | RTECS | GY2370000 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral | | Toxicity | hamster,LD50,intraperitoneal,> 500mg/kg (500mg/kg),Toxicology Letters. Vol. 30, Pg. 159, 1986. |
| | nimbolide Usage And Synthesis |
| Chemical Properties | Light Beige Solid | | Uses | Nimbolide, a natural triterpenoid present in the edible parts of the neem tree (Azadirachta indica), was found to be growth-inhibitory in human colon carcinoma HT-29 cells. Nimbolide treatment of cells at 2.5 - 10 μM resulted in moderate to very strong growth inhibition. | | Biological Activity | Nimbolide exhibits anti-malarial, anti-bacterial, and anti-cancer activities. It has been shown to induce apoptosis in osteosarcoma cells and inhibits cell migration of these cells by modulating the expression of integrin αvβ5. In human renal carcinoma cells, nimbolide induced cell cycle arrest, DNA damage, and apoptosis.It has been shown to modulate autophagy and apoptosis in pancreatic cancer. | | in vivo | Nimbolide (10 mg/kg, i.v., daily, 7 days) inhibits glioblastoma multiforme tumor growth in U87EGFRvⅢ xenografted mouse model[2].
Nimbolide (5 mg/kg, 20 mg/kg; i.p.; daily, 10 days), inhibits tumor growth in HCT-116-derived xenograft mouse, reduces the expression of proteins involved in invasion, metastasis, and angiogenesis (MMP-9, CXCR4, ICAM-1, and VEGF)[5].
| Animal Model: | HCT-116-derived xenograft mouse[5] | | Dosage: | 5 mg/kg, 20 mg/kg | | Administration: | Intraperitoneal injection (i.p.), daily, 10 days | | Result: | Suppressed tumor growth in nude mice at a dose as low as 5 mg/kg.
Reduced tumor growth by almost 90% on day 10 at a dose as low as 20 mg/kg.
Didn’t affect the body weight of mice.
|
| | IC 50 | NF-κB; CDK4; CDK6 | | storage | Store at -20°C |
| | nimbolide Preparation Products And Raw materials |
|